08:00 , Nov 12, 2001 |  BC Week In Review  |  Company News

Afferon, Icos deal

ICOS exclusively licensed from Afferon worldwide rights to RTX resiniferatoxin to treat urological disorders. ICOS will pay Afferon an upfront license fee, milestones and royalties, and will fund development of RTX and its analogs. ICOS...
08:00 , Nov 5, 2001 |  BC Extra  |  Company News

Icos licenses Afferon's RTX

ICOS exclusively licensed from Afferon (Wayne, Penn.) worldwide rights to RTX resiniferatoxin to treat urological disorders. ICOS will pay an upfront license fee, milestones and royalties. In addition, ICOS develop and commercialize RTX and its...
08:00 , Jan 24, 2000 |  BC Week In Review  |  Clinical News

RTX resiniferatoxin: Began Phase II study

Afferon Corp., Wayne, Penn.   Product: RTX resiniferatoxin   Business: Urological, Neurological   Therapeutic category: Neurotransmission   Target: Peripheral sensory neurons   Description: Neuronal desensitizing agent   Indication: Treat overactive bladder   Status: Afferon began a dose-finding placebo-controlled U.S. Phase II study...
08:00 , Jan 19, 2000 |  BC Extra  |  Clinical News

Afferon begins resiniferatoxin Phase II

Afferon began a dose-finding placebo-controlled U.S. Phase II study to examine the safety and efficacy of RTX resiniferatoxin Topical Solution in 45 patients with overactive bladder due to neurological conditions. Afferon (Wayne, Penn.) partner Mundipharma...
07:00 , Sep 7, 1999 |  BC Week In Review  |  Company News

Afferon board of directors update

Afferon Corp., Wayne, Penn.   Business: Urological   Appointed: Robert Easton, former president of The Wilkerson Group; and Stuart Samuels, former SVP of Rorer Pharmaceutical Corp.   ...
07:00 , Jul 12, 1999 |  BC Week In Review  |  Clinical News

RTX resiniferatoxin: Expanded Phase II studies

Afferon Corp., Wayne, Penn.   Product: RTX resiniferatoxin   Business: Urological, Neurological   Therapeutic category: Neurotransmission   Target: Peripheral sensory neurons   Description: Neuronal desensitizing agent   Indication: Treat overactive bladder   Status: Afferon and partner Mundipharma will expand their Phase II...
07:00 , May 3, 1999 |  BioCentury  |  Emerging Company Profile

Afferon Corp.

Afferon Corp. Wayne, Penn. Technology: Vanilloid compounds Disease focus: Urge incontinence and pain Clinical status: Phase II Founded: 1992 by Richard Herman, Frank Porreca, Steve Buck and Hank Agersborg Corporate partners: Mundipharma University collaborators: None Number...
07:00 , May 3, 1999 |  BC Week In Review  |  Company News

Afferon, Mundipharma deal

Mundipharma, an affiliate of The Purdue Frederick Co. (Norwalk, Conn.), received an exclusive license to market in Europe and the Middle East Afferon’s Resiniferatoxin (RTX) vanilloid compound to treat incontinence associated with overactive bladder....
07:00 , May 3, 1999 |  BioCentury  |  Emerging Company Profile

Afferon: A bankroll against urge incontinence

Afferon Corp. is developing vanilloid compounds with a focus on urology. The company believes that its lead product, resiniferatoxin (RTX), has advantages over marketed treatments for urge incontinence in both side effect profile and compliance...
07:00 , Sep 21, 1998 |  BC Week In Review  |  Clinical News

Resiniferatoxin: Phase II

Afferon said that preliminary results from a European Phase I/II trial showed improvement in 10 of 14 patients in such symptoms as urination frequency, urine loss, and bladder capacity, with no adverse events. The...